Gilead fails to overturn $752M CAR-T patent verdict. Will BMS win case for larger penalties?

lady justice
Gilead and BMS are locked in a CAR-T patent fight, with BMS scoring wins so far. (Getty Images)

Bristol Myers Squibb and Gilead Sciences have been locked in a CAR-T patent fight, with BMS scoring a lucrative victory following a trial late last year. Now, Gilead has failed to persuade a judge to overturn the $752 million verdict—and the company could face bigger damages down the line.  

In an order unsealed earlier this week, Judge James Otero rejected numerous arguments from Gilead’s Kite Pharma unit that patents held by BMS’ Juno Therapeutics are invalid, plus that procedural flaws in the legal process warrant a new trial. 

Kite’s “current arguments largely mirror its previous arguments,” the judge wrote in the March 24 order. The court rejected Kite’s arguments for a new trial on grounds of unfair time limits, prejudice, and more. 


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

RELATED: Jury orders Gilead's Kite Pharma to pay $752M for CAR-T patent infringement 

In its own post-trial motion, Juno Therapeutics petitioned for a larger verdict of $1.5 billion. In the motion, Juno said Kite’s “egregious, willful infringement warrants a punitive award in the same amount as the compensatory award." The company also cited concerns about Kite’s legal strategy as reasons to expand the award. 

As for the Tuesday decision, BMS is "pleased that the court has denied Kite's ... attempt to overturn the jury’s verdict that confirmed the validity of the ’190 patent and found that Kite willfully infringed the patent," a representative said. A spokesman for Kite didn't immediately respond to a request for comment.

RELATED: CAR-T patent damages at $1.5B? BMS urges court to hike $752M award against Gilead 

The order comes after the December jury verdict in favor of Juno in the amount of $752 million. Juno originally sued in 2017, arguing Kite “copied and is now commercializing" CAR-T technology invented and patented by scientists at Sloan Kettering. Juno exclusively licensed the '190 patent from Sloan Kettering and the Memorial Sloan Kettering Cancer Center in November 2013, the lawsuit said. 

The drugmaker argues that Kite scientific collaborators lifted the work that led to the development of Yescarta, the centerpiece in a $12 billion buyout by Gilead Sciences. Yescarta generated $456 million last year, and those sales were part of the court’s damages calculation.